Clinical relevance of anti‐exenatide antibodies: safety, efficacy and cross‐reactivity with long‐term treatment
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims: Antibody formation to therapeutic peptides is common. This analysis characterizes the time‐course and cross‐reactivity of anti‐exenatide antibodies and potential effects on efficacy and safety. Methods: Data from intent‐to‐treat patients in 12 controlled (n = 2225,12–52weeks) and 5 uncontrolled (n = 1538, up to 3 years) exenatide twice‐daily (BID) trials and 4 controlled (n = 653,24–30weeks) exenatide once weekly (QW) trials with 1 uncontrolled period (n = 128,52weeks) were analysed. Results: Mean titres peaked early (6–22 weeks) and subsequently declined. At 30 weeks, 36.7% of exenatide BID patients were antibody‐positive; 31.7% exhibited low titres (≤125) and 5.0% had higher titres (≥625). Antibody incidence declined to 16.9% (1.4% higher titre) at 3 years. Similarly, 56.8% of exenatide QW patients were antibody‐positive (45.0% low/11.8% higher titre) at 24–30 weeks, declining to 45.4% positive (9.2% higher titre) at 52 weeks. Treatment‐emergent anti‐exenatide antibodies from a subset of patients tested did not cross‐react with human GLP‐1 or glucagon. Other than injection‐site reactions, adverse event rates in antibody‐positive and antibody‐negative patients were similar. Efficacy was robust in both antibody‐negative and antibody‐positive patients (mean HbA1c change: −1.0 and −0.9%, respectively, exenatide BID; −1.6% and −1.3% exenatide QW). No correlation between change in HbA1c and titre was observed for exenatide BID, although mean reductions were attenuated in the small subset of patients (5%) with higher titres. A significant correlation was observed for exenatide QW with no difference between antibody‐negative and low‐titre patients, but an attenuated mean reduction in the subset of patients (12%) with higher titres. Conclusions: Low‐titre anti‐exenatide antibodies were common with exenatide treatment (32% exenatide BID, 45% exenatide QW patients), but had no apparent effect on efficacy. Higher‐titre antibodies were less common (5% exenatide BID, 12% exenatide QW) and within that titre group, increasing antibody titre was associated with reduced average efficacy that was statistically significant for exenatide QW. Other than injection‐site reactions, anti‐exenatide antibodies did not impact the safety of exenatide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“Entry criteria, background therapy, randomization, demographics, study design and outcomes have been described previously [1,15–29].”
MethodSelf-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Self-citationKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 1×
“com same as that approved for BID administration, exenatide QW shows greater improvement in glycaemic control as a result of continuous drug exposure with no increased risk of hypoglycaemia in clinical trials [1].”
BackgroundSelf-citationEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 1×
“Exenatide shares less sequence homology with GLP-1 (53%) [38] than liraglutide does (97%) [39], which may underlie the higher incidence of antibodies against exenatide, as well as the lack of cross-reactivity with GLP-1 and the sequence-related hormone glucagon.”
BackgroundHeine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 1×
“Entry criteria, background therapy, randomization, demographics, study design and outcomes have been described previously [1,15–29].”
MethodDiamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · cited 1×
“Entry criteria, background therapy, randomization, demographics, study design and outcomes have been described previously [1,15–29].”
MethodSelf-citationMoretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350 · cited 1×
“Entry criteria, background therapy, randomization, demographics, study design and outcomes have been described previously [1,15–29].”
Method
Cited by
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
“Those with high antibody titers overall had a smaller improvement in hemoglobin A1C values; however, there was no correlation found in hemoglobin A1C values between patients with negative titers versus those with low titers [74].”
Metadata
- Authors
- Fineman, M. S., Mace, K. F., Diamant, M., Darsow, T., Cirincione, B. B., Booker Porter, T. K., Kinninger, L. A., & Trautmann, M. E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-02-10
- Volume
- 14
- Issue
- 6
- Pages
- 546-554
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2009288620
- Cited by
- 152
- References
- 11
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical relevance of anti‐exenatide antibodies: safety, efficacy and cross‐reactivity with long‐term treatment. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01561.x
- The paper
- Fineman, M. S., Mace, K. F., Diamant, M., Darsow, T., Cirincione, B. B., Booker Porter, T. K., Kinninger, L. A., & Trautmann, M. E. (2012). Clinical relevance of anti‐exenatide antibodies: safety, efficacy and cross‐reactivity with long‐term treatment. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01561.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.